Chitin Or Derivative Patents (Class 514/55)
-
Publication number: 20140274943Abstract: The present invention is directed to a composition for treating bacterial skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antibacterial active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of silver sulphadiazine used in treating bacterial skin infections, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water.Type: ApplicationFiled: April 5, 2010Publication date: September 18, 2014Applicant: APEX LABORATORIES PRIVATE LIMITEDInventors: Vanangamudi Sulur Subramaniam, Srinivasan Madhavan, Neelakandan Narayanan Chulliel, Kuppusamy Senthilkumar
-
Patent number: 8835486Abstract: An improved pharmaceutical formulation for oral administration includes a therapeutically effective quantity of an active ingredient and a stabilizer. The active ingredient is Fluvastatin, or pharmaceutically acceptable salts thereof, and the stabilizer is a mixture of Carrageenans. The stabilizer inhibits isomerization, and/or elimination, and/or oxidation and/or recrystallization of the active ingredient.Type: GrantFiled: May 12, 2006Date of Patent: September 16, 2014Inventors: Evangelos Karavas, Efthimios Koutris, Elisavet Ioannidou, Eleni Stathaki, Dimitrios Bikiaris
-
Patent number: 8828968Abstract: A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×103-9×105, and the amount of free amino groups in the glucidamin is in the range of 50%-100% based on the total amino groups. The preparation method of the nanoparticle comprises steps listed below: (1) adding the glucidamin possessing one or more molecular weight into thin acid solution at 20-60° C. to form saccharan solution, wherein the content of saccharan in solution is in the range of 0.1%-5% by weight; (2) adjusting the pH of the solution to 6-9 in order to form emulsion of microparticle; (3) separating the microparticle from the emulsion, dried at low temperature to obtain the nanoparticle of glucidamin for treating tumor. The nano-class glucidamin can enhance their activity against tumor.Type: GrantFiled: May 22, 2007Date of Patent: September 9, 2014Assignee: Ningbo Puai Bioengineering Co., Ltd.Inventor: Zirong Xu
-
Publication number: 20140249102Abstract: A topical applicator composition and process are described that decorporate radionuclides from radiologically-contaminated dermal surfaces and that further promote healing. The topical applicator includes a decorporation agent mixed with a plasticizing agent that forms a covering when applied to the dermal surface that decorporates radionuclides and minimizes their systemic migration. The topical applicator formulations can be delivered in conjunction with bandages and other application dressings.Type: ApplicationFiled: June 30, 2011Publication date: September 4, 2014Applicant: BATTELLE MEMORIAL INSTITUTEInventors: Tatiana G. Levitskaia, Karla D. Thrall, James M. Peterson, Glen E. Fryxell, Charles A. Timchalk, Barbara J. Tarasevich
-
Publication number: 20140242024Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicant: Covidien LPInventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla, Timothy Sargeant, Joshua Stopek
-
Patent number: 8809301Abstract: A composition suitable for use in wound healing, particularly for reducing post-surgical adhesions, containing cross-linked derivatives of chitosan and dextran polymers. A hydrogel forms when solutions of the polymers are combined.Type: GrantFiled: May 3, 2013Date of Patent: August 19, 2014Assignees: Adelaide Research & Innovation Pty Ltd, Robinson Squidgel Ltd, Otago Innovation LtdInventors: Theodore Athanasiadis, Lyall Robert Hanton, Stephen Carl Moratti, Brian Harford Robinson, Simon Rae Robinson, Zheng Shi, James Simpson, Peter John Wormald
-
Patent number: 8802117Abstract: The present invention relates to synergistic associations of melatonin and other active substances and cosmetic compositions suitable for treating all those manifestations causing or accompanying the aging of skin, hair and other tissues. In particular, the invention is based on the use of melatonin associated with immunoactive and antioxidant substances significantly potentiating its antiaging activity, remarkably reducing free radical formation and thereby improving the aspect of both skin and hair.Type: GrantFiled: March 2, 2007Date of Patent: August 12, 2014Assignee: Mavi Sud S.r.l.Inventor: Pierfrancesco Morganti
-
Patent number: 8802652Abstract: Tissue and other body structures may be protected using a hydrated composition made from free-flowing substantially collagen-free rehydratable polysaccharide particles and rehydratable polysaccharide sponges. Rehydration of the particles without clumping may be carried out be dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated composition may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function.Type: GrantFiled: April 23, 2009Date of Patent: August 12, 2014Assignee: Medtronic, Inc.Inventors: Matthew Franco Myntti, Dana A. Oliver, Brian Vaccaro
-
Publication number: 20140219962Abstract: Porous chitosan scaffold having high mechanical strength, methods for making the porous chitosan scaffold, and method for using the porous chitosan scaffold.Type: ApplicationFiled: January 30, 2014Publication date: August 7, 2014Applicant: University of Washington through its Center for CommercializationInventors: Miqin Zhang, Soumen Jana
-
Publication number: 20140221308Abstract: A method of treating a surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g., soluble or derivatized chitosan) with the surface, thereby treating the surface. Non-pharmaceutical compositions (e.g., liquid or dry powder compositions) include chitosan (e.g., a soluble or derivatized chitosan). The compounds and compositions described herein are biocompatible (e.g., non-toxic) and/or biodegradable (e.g., eco-friendly). Methods using the compositions described herein include methods of treating a surface (e.g., an inert and/or non-animal surface, e.g., a synthetic or semi-synthetic surface (e.g., cellulose, ceramic, plastic, metal, glass, wood, or stone); or a food or food product surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g.Type: ApplicationFiled: June 29, 2012Publication date: August 7, 2014Applicant: SYNEDGEN, INC.Inventors: Shenda Baker, William P. Wiesmann, Stacy M. Townsend
-
Publication number: 20140213548Abstract: The present invention relates a novel hemostatic wound dressing, preferably comprising chitosan and an oxygen carrier such as a perfluorocarbon, and methods to treat hemorrhaging wounds and MRSA infections. The present invention helps with coagulation/clot formation as well as providing oxygen to the wound, all while being cost effective and competitive with current hemostatic dressings.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Applicant: New Jersey Institute of TechnologyInventors: George J. Ulsh, Jennifer W. Moy, Maxwell A. McDermott, Dung T. Le, George Colling, Jessica Cardenas Turner
-
Publication number: 20140212457Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes. Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.Type: ApplicationFiled: August 12, 2013Publication date: July 31, 2014Inventor: Abdalla Rifai
-
Publication number: 20140206642Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.Type: ApplicationFiled: March 24, 2014Publication date: July 24, 2014Applicant: Cutanea Life Sciences, Inc.Inventors: Robert Bitterman, Kimberley A. Forbes-McKean
-
Publication number: 20140194379Abstract: Methods for the production chitin nanofibers and uses thereof. Furthermore, methods for the production of chitin nanofibers and the fabrication of chitin nanofiber structures and devices.Type: ApplicationFiled: June 1, 2012Publication date: July 10, 2014Applicant: University of Washington Through Its Center For CommercializationInventors: Marco Rolandi, Ronald Berenson, Vittorio Ruvolo, Adnan Kapetanovic, Jungho Jin, Chao Zhong
-
Publication number: 20140193476Abstract: The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicants: NANYANG TECHNOLOGICAL UNIVERSITY, MENICON CO., LTD.Inventors: Chan Bee Eng Mary, Poon Yin Fun, Mouad Lamrani, Shinichi Hamaguchi
-
Publication number: 20140193360Abstract: The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same.Type: ApplicationFiled: November 21, 2011Publication date: July 10, 2014Applicant: Innotherapy Inc.Inventors: Haeshin Lee, Moon Sue Lee, Ji Hyun Ryu
-
Publication number: 20140178446Abstract: This invention relates to deployable hemostatic materials comprising chitosan fibers. The hemostatic materials are suitable for use in sealing or controlling active bleeding from artery and vein lacerations and punctures, and for controlling oozing from tissue.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: Loma Linda University Medical CenterInventors: Yong Hua Zhu, Chang Zheng Yang, Wolff M. Kirsch
-
Publication number: 20140171385Abstract: Biodegradable materials are formed by mixing together two or more materials which have different resorption times and different mechanical characteristics. Devices formed of these materials can be used in mammals in numerous medical and surgical applications, including those for which the mechanical properties of the device, left in vivo, much change over time.Type: ApplicationFiled: December 13, 2013Publication date: June 19, 2014Applicant: ECD MEDICALInventors: Fred Burbank, Michael Jones
-
Patent number: 8753697Abstract: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.Type: GrantFiled: September 24, 2009Date of Patent: June 17, 2014Assignee: Nutramax Laboratories, Inc.Inventors: Todd R. Henderson, Tarek Hammad, Medhat Soliman, Barbara Corson, Louis Lippiello, Robert Henderson
-
Publication number: 20140162977Abstract: An anti-microbial absorbent chitosan, optionally in the form or fibres, derivatised by treatment with high energy, in particular gamma, radiation, a non-woven fabric and an absorbent device comprising the derivatised chitosan, methods for the preparation of such a chitosan, non-woven fabric and an absorbent device, and the use of said absorbent device in wound care.Type: ApplicationFiled: May 10, 2012Publication date: June 12, 2014Applicant: Medtrade Products LimitedInventor: Christian Stephenson
-
Patent number: 8741335Abstract: Improved hemostatic agents take the form of granules or particles that can be used to stanch, seal, or stabilize a site of hemorrhage, including a noncompressible hemorrhage.Type: GrantFiled: July 13, 2006Date of Patent: June 3, 2014Assignee: HemCon Medical Technologies, Inc.Inventor: Simon J. McCarthy
-
Patent number: 8741270Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.Type: GrantFiled: February 21, 2013Date of Patent: June 3, 2014Assignee: Alumend, LLCInventors: Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska
-
Publication number: 20140147401Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: POLICHEM SAInventor: Federico MAILLAND
-
Publication number: 20140134271Abstract: Pyrimidine compounds and their use in controlling pests such as insects and other invertebrates are provided. Further embodiments, forms, objects, features, advantages, aspects and benefits shall become apparent from the description.Type: ApplicationFiled: October 25, 2013Publication date: May 15, 2014Applicant: Dow AgroSciences LLCInventors: Tony K. Trullinger, Timothy C. Johnson, Ricky Hunter
-
Patent number: 8722127Abstract: Bakery products and pasta with added chitosan are disclosed. The chitosan is addified with a biologically acceptable acid and added to pasta and baked products. Once the baked products and/or pasta are ingested, gastro-intestinal absorption of fats is limited even after cooking.Type: GrantFiled: February 2, 2006Date of Patent: May 13, 2014Assignee: Cor. Con. International S.R.L.Inventor: Umberto Cornelli
-
Patent number: 8722646Abstract: The invention provides highly concentrated chitosan-nucleic acid polyplex compositions and dispersions, and methods for producing the compositions and dispersions. Methods of mixing the chitosan-nucleic acid polyplexes include an inline mixing of chitosan solution and nucleic acid solution, followed by further concentrating the dispersion of chitosan-nucleic acid polyplexes, optionally with an aggregation inhibitor. Further provided are methods for altering the diameter of chitosan-nucleic acid polyplexes.Type: GrantFiled: September 26, 2008Date of Patent: May 13, 2014Assignee: enGene, Inc.Inventors: Eric Hsu, Carlos Fleet, Anthony Cheung, Jun Gao
-
Patent number: 8722081Abstract: A hemostatic textile material to stop bleeding comprising a dialdehyde cellulose (DAC) carrier wherein the degree of oxidation of the dialdehyde cellulose varies from about 1.5% to 12%; and a blood coagulation factor selected from the group consisting of chitosan and gelatin; the blood coagulation factor being chemically immobilized thereon; and further optionally comprising a bacteriolytic agent selected from the group consisting of a lysozyme enzyme, silver nitrate, and chlorhexidine; and further optionally comprising a selected component that prevents hemolysis, the component selected from the group consisting of tranexamic acid or ?-aminocaproic acid chemically immobilized thereon.Type: GrantFiled: October 15, 2007Date of Patent: May 13, 2014Inventors: Vladimir N. Filatov, Vladimir Ryltsev, Zidkiyahu Simenhaus
-
Patent number: 8715719Abstract: A method of preparing a stable chitosan hemostatic implant including preparing a lyophilizable solution of chitosan polymers and freezing the solution to obtain a frozen chitosan composition. The method further includes placing the frozen chitosan composition under vacuum so as to substantially dry the chitosan composition and curing the dried chitosan composition by first exposing it to a relative humidity and then curing the dried chitosan composition under heat so as to crosslink the chitosan polymers.Type: GrantFiled: June 16, 2010Date of Patent: May 6, 2014Assignee: Abbott Vascular, Inc.Inventors: Wouter E. Roorda, Jill A. McCoy, Richard Seto, Eugene T. Michal
-
Patent number: 8709470Abstract: The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices.Type: GrantFiled: July 13, 2009Date of Patent: April 29, 2014Assignees: Menicon Co., Ltd., Nanyang Technological UniversityInventors: Chan Bee Eng Mary, Poon Yin Fun, Mouad Lamrani, Shinichi Hamaguchi
-
Patent number: 8709996Abstract: The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight of 1 KDa or less, a peptide, a protein or a polysaccharide. The compositions of the invention provide enhance absorption of the drug compound.Type: GrantFiled: April 23, 2010Date of Patent: April 29, 2014Assignee: Archimedes Development LimitedInventors: Michael Leane, Alan Smith, Lisbeth Illum
-
Patent number: 8710028Abstract: A powder composition for intranasal delivery includes a benzodiazepine drug and chitosan, a salt of chitosan, a derivative of chitosan or a salt of a derivative of chitosan.Type: GrantFiled: August 29, 2008Date of Patent: April 29, 2014Assignee: Archimedes Development LimitedInventors: Peter James Watts, Yu-Hui Cheng, Alan Smith, Jonathan Castile
-
Publication number: 20140113881Abstract: The present invention relates to the use of hydroxymethyl-group-containing glycosaminoglycans, such as in particular hydroxymethyl-hyaluronic acid, for the treatment and prevention of infectious diseases or malignant or premalignant diseases, in particular of the skin or mucosa. The invention additionally provides a preparation method for glycosaminoglycans modified with hydroxymethyl groups.Type: ApplicationFiled: June 8, 2012Publication date: April 24, 2014Inventors: Johannes Reinmuller, Kay Dirting
-
Patent number: 8703924Abstract: This invention relates to a cross-linkable chitosan composition comprising chitosan having a degree of deacetylation between 30 and 75%, wherein the chitosan is randomly deacetylated, and a cross-linking agent, wherein the molar ratio of the cross-linking agent to chitosan is 0.2:1 or less based on the number of functional groups in the cross-linking agent and the number of accessible amino groups in the chitosan. The invention also provides a chitosan hydrogel formed therefrom and uses thereof.Type: GrantFiled: October 30, 2008Date of Patent: April 22, 2014Assignee: Viscogel, ABInventor: Mats Andersson
-
Publication number: 20140105876Abstract: The invention relates to a ceramic biocomposite for bone regeneration, having a pH range of between 6.5 and 8.5, with an initial plasticity that allows the biocomposite to be easily moulded in situ and to set after 7 minutes, meaning that it can remain at the indicated location during the healing process. In addition, the biocomposite has demonstrated an ability to stimulate bone formation in hard-to-heal wounds. The material can act alone or in combination with other types of bone graft such as autografts, homografts or xenografts which act as a vehicle, as a binding material for endosseous prostheses or as a covering for endosseous implants or prostheses.Type: ApplicationFiled: March 27, 2012Publication date: April 17, 2014Applicant: UNIVERSIDAD AUTONOMA DE OCCIDENTEInventors: Sandra Arce Guerrero, Carlos Humberto Valencia
-
Publication number: 20140107065Abstract: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug.Type: ApplicationFiled: July 16, 2013Publication date: April 17, 2014Inventors: Weiliam Chen, John M. Abrahams
-
Publication number: 20140107015Abstract: There is provided a pharmaceutical composition for preventing or treating human immunodeficiency virus, and more particularly, to a pharmaceutical composition and health functional food for preventing or treating/improving human immunodeficiency virus, the pharmaceutical composition and health functional food including a new compound with chitooligosaccharides conjugated amino acids or dipeptides as an effective component. The new compound has an excellent anti-HIV effect through an activity of inhibiting a HIV initial infection by interrupting an interaction between host-virus membranes, and also activities of inhibiting reverse transcriptase and protease of HIV. The compound according to the present invention is a conjugate synthesized through conjugating chitooligosaccharides derived from a natural material with amino acids or dipeptides. The compound is stable without cytotoxicity.Type: ApplicationFiled: November 13, 2012Publication date: April 17, 2014Applicant: Pukyong National University Industry-University Cooperation FoundationInventors: Se-Kwon KIM, Fatih KARADENIZ
-
Patent number: 8697672Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.Type: GrantFiled: May 16, 2008Date of Patent: April 15, 2014Assignee: California Institute of TechnologyInventors: David Baltimore, Ryan O'Connell, Konstantin Taganov, Mark Boldin
-
Patent number: 8691973Abstract: Provided are a method of producing a porous chitosan scaffold, the method including: providing an aqueous acidic solution having chitosan and a solvent which does not dissolve the chitosan; and freeze-drying the aqueous acidic solution, wherein the solvent is selected from the group consisting of a C3-C8 aliphatic alcohol having one hydroxy group, ethylene glycol monoethylether, ethylene glycol monobutylether, dioxane, tetrahydrofuran, dimethylcarbonate, acetone and acetonitrile, and a chitosan scaffold produced using the method.Type: GrantFiled: February 21, 2007Date of Patent: April 8, 2014Assignee: Korea Institute of Radiological & Medical SciencesInventors: Chun-Ho Kim, Seung-Jae Lee, Jin-Ik Lim, Youngsook Son
-
Patent number: 8685946Abstract: The present invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner. RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway, and methods of use thereof. The RISC inactivators of the present invention enable a variety of methods for identifying and characterizing miRNAs and siRNAs, RISC-associated factors, and agents capable of modulating RNA silencing. Therapeutic methods and compositions incorporating RISC inactivators and therapeutic agents identified through use of RISC inactivators are also featured.Type: GrantFiled: November 26, 2004Date of Patent: April 1, 2014Assignee: Universiy of MassachusettsInventors: György Hutvágner, Phillip D. Zamore
-
Patent number: 8680074Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.Type: GrantFiled: February 7, 2008Date of Patent: March 25, 2014Assignee: Polichem SAInventor: Federico Mailland
-
Publication number: 20140079663Abstract: The invention relates to inhibitory compounds of a p38 MAP kinase having a structure of type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. Pharmaceutical compositions are disclosed containing an effective amount of the substance SB203580 or one or more of the conjugated compounds of type (I)-(VII) or a combination thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is a method for the prophylaxis and/or treatment of a disease or a condition in which there is a possibility of the formation and/or growth of adhesions, which makes it possible to dispense with the additional administration of a preparation in the post-operative period.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicant: Joint Stock Company "Pharmasyntez"Inventors: Mikhail Gennadievich Shurygin, Irina Aleksandrovna Shurygina
-
Publication number: 20140072657Abstract: The present invention provides novel compositions comprising chitosan and vitamin D or chlorhexidin and vitamin D for the treatment of mucosal and epithelial wounds and for the treatment or prevention of oral, mucosal or dermal infections or inflammations.Type: ApplicationFiled: May 11, 2012Publication date: March 13, 2014Inventor: Helmut Vockner
-
Publication number: 20140073601Abstract: Bodily tissue and structures may be protected using a fluid layer containing a mixture of chitosan and oxidized polysaccharide. The mixture forms a protective gel layer via in situ crosslinking. Compared to crosslinking using a low molecular weight aldehyde such as glutaraldehyde or genipin, oxidized polysaccharides appear to provide faster gelation while avoiding the use of potentially less bioacceptable low molecular weight aldehydes.Type: ApplicationFiled: November 13, 2013Publication date: March 13, 2014Applicant: Medtronic, Inc.Inventors: Edze Jan Tijsma, Maria Nieves Gonzalez, Erica M. TenBroek, Nancy Schaffhausen
-
Patent number: 8668924Abstract: This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer, a polyacrylic polymer or a combination thereof, The kind of severe, life-threatening bleeding contemplated by this invention is typically of the type not capable of being stanched when a conventional gauze wound dressing is applied with conventional 10 pressure to the subject wound. The wound dressing being capable of substantially stanching the flow of the severe life-threatening bleeding from the wound by adhering to the wound site, to seal the wound, to accelerate blood clot formation at the wound site, to reinforce clot formation at the wound site and prevent bleed out from the wound site, and to substantially prohibit the flow of 15 blood out of the wound site.Type: GrantFiled: October 18, 2010Date of Patent: March 11, 2014Assignees: Providence Health System—OregonInventors: Simon J. McCarthy, Kenton W. Gregory, William P. Wiesmann, Todd D. Campbell
-
Patent number: 8664199Abstract: A method for reversing gelation of hydrophobically modified biopolymer attached to vesicle or cell membranes. The gelation of hydrophobically modified biopolymer attached to vesicles or cell membranes is reversed by application of a supramolecule, such as cyclodextrin, to the gelled composition. The supramolecule disrupts the interactions between the hydrophobically modified biopolymer and the vesicle or cell membrane, without affecting the structure of the membrane or the hydrophobically modified polymer to which the hydrophobic substituents are attached. A kit for treating wounds that includes a hydrophobically modified biopolymer and a supramolecule. The hydrophobically modified biopolymer is used to stop bleeding and the supramolecule is used to remove the hydrophobically modified biopolymer.Type: GrantFiled: August 13, 2011Date of Patent: March 4, 2014Assignee: University of Maryland, College ParkInventors: Matthew Dowling, Srinivasa R. Raghavan, Rakesh Kumar
-
Patent number: 8664198Abstract: A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host.Type: GrantFiled: February 28, 2011Date of Patent: March 4, 2014Assignee: The University of Central OklahomaInventor: Wei R. Chen
-
Patent number: 8658775Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.Type: GrantFiled: December 13, 2011Date of Patent: February 25, 2014Inventors: Shenda Baker, William P. Wiesmann, Shannon Ryan
-
Publication number: 20140045761Abstract: Methods and devices for determining the healing status of wounds, in particular of chronic wounds are provided. Also provided are kits comprising the diagnostic devices, and methods of wound diagnosis and treatment using the diagnostic devices and methods. A diagnostic apparatus (device) for monitoring wounds that exude a wound fluid and determining whether said wounds would be responsive to treatment with wound therapy such as oxidized cellulose therapy is also provided along with kits comprising the diagnostic apparatus and a wound dressing. Furthermore, methods of prognosing and treating wounds that exude a wound fluid are also provided.Type: ApplicationFiled: January 31, 2012Publication date: February 13, 2014Applicant: Systagenix Wound Management IP CO. BVInventor: Molly Gibson
-
Publication number: 20140044758Abstract: A wound dressing with bacteriostatic and hygroscopicity, preparation method therefore, and the use thereof in preparing a product for treating chronic wounds. The dressing comprises chitosan fiber and modified cellulose fiber.Type: ApplicationFiled: March 2, 2012Publication date: February 13, 2014Inventors: Xiaodong Wang, Dawei Zhang, Xiaohui Mo, Qiulan Lv, Zhenjun Wu
-
Patent number: 8642088Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.Type: GrantFiled: September 3, 2010Date of Patent: February 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo